Bruker Daltonics Announces Selection of its Range of Chemical Agent Detectors for Slovenian Armored Vehicles.

LEIPZIG, Germany -- Bruker Daltonik GmbH today announced that it was awarded a $3.5 million contract to supply the Slovenian Army with a series of long range and point chemical detectors for integration into Slovenia's new lightweight reconnaissance vehicles. This contract has been awarded in cooperation with Em.tronic d.o.o., a Slovenian defense contractor. The Bruker Daltonics equipment to be supplied consists of RAPID(TM) infrared chemical standoff detectors, RAID-S2TM ion mobility spectrometers (IMS) for vehicle air monitoring and RAID-M100TM IMS systems for hand-held chemical agent detection. The equipment will be delivered over the next two years.

Bruker's RAPID(TM) is the leading long-range standoff chemical warfare agent detector for remote detection of hazardous gases up to a distance of several kilometers.

The RAID-S2TM is designed for integration into vehicles, ships and facilities to measure chemical agents in ambient air, both inside and outside with dual sampling capability.

The acclaimed RAID-M 100TM hand-held chemical agent monitor is for use by troops dismounting the vehicles for both personal protection and surveillance activities.

Dr. Joachim Stach, Director for Marketing and Sales for Bruker CBRN equipment, commented: "We are very pleased with this selection by the Slovenian Armed Forces for their chemical agent detection equipment program. This contract further solidifies Bruker's position as the premier provider of detection instruments for military vehicle programs. We are also looking forward to working with Em.tronic as one of our new European partners."

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics Inc. Bruker Daltonics provides a broad range of field analytical systems for Chemical, Biological, Radiological, and Nuclear (CBRN) detection. For more information, please visit www.bruker-biosciences.com

BRUKER BIOSCIENCES CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.